{"id":3034,"date":"2026-09-10T09:00:00","date_gmt":"2026-09-10T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3034"},"modified":"2026-09-10T19:57:27","modified_gmt":"2026-09-10T23:57:27","slug":"bhv-7000-epilepsy-enrollment-paused-after-fda-partial-hold","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3034","title":{"rendered":"BHV-7000 Epilepsy Enrollment Paused After FDA Partial Hold"},"content":{"rendered":"

Evidence<\/strong> Regulatory disclosure · Discovery<\/strong> September 10, 2026 · Importance<\/strong> 5\/5 · Direction<\/strong> Negative<\/p>\n

\"BHV-7000<\/p>\n

Summary<\/h4>\n

The FDA placed a partial clinical hold on Biohaven’s BHV-7000 epilepsy program after requesting more information about a specific metabolite observed in rodent testing. New enrollment is paused in the ongoing epilepsy studies, while dosing continues for more than 600 randomized participants. The fully enrolled RISE3 study remains on track for a second-half 2026 topline readout; RISE2 enrollment is paused. The hold is a material regulatory and execution setback, but its human relevance is not yet established.<\/p>\n

What Happened<\/h4>\n

Biohaven disclosed that the FDA issued the partial hold on September 4 and voluntarily paused new enrollment at sites outside the United States. Participants already randomized may continue dosing, including those in extension treatment. The agency’s request concerns inadequate information about potential human risk from a metabolite detected in rodent studies. Biohaven said it expects additional nonclinical work within weeks and reported no adverse event directly linked to the finding among more than 1,200 people exposed to BHV-7000. The company also said the metabolite characterization had been disclosed to SK Biopharmaceuticals before the companies signed their August 26 global Kv7-platform transaction, which has not yet closed.<\/p>\n

Deep Analysis<\/h4>\n

A resolvable, rodent-specific signal:<\/strong> The current issue is not a demonstrated clinical toxicity; it is an unresolved nonclinical-to-human translation question. Substantial human exposure without a disclosed matching adverse-event pattern and continued dosing under the partial hold support the possibility of bridging studies allowing enrollment to resume without changing the pivotal program. Contradicting evidence is the FDA’s determination that current information was insufficient to exclude human risk.<\/p>\n

A human safety or dose-margin constraint:<\/strong> The cross-program, global voluntary enrollment pause supports the possibility that the metabolite creates a real constraint that delays or changes development. Against it, no clinical event has been causally associated with the finding, and RISE3 is fully enrolled. Exposure margins, metabolite identity, species specificity and tissue distribution were not disclosed.<\/p>\n

Signal Extraction<\/h4>\n

Verified facts: partial hold; new-enrollment pause; continued dosing for more than 600 randomized participants; more than 1,200 cumulative exposures; RISE3 remains scheduled for second-half 2026 topline data. Missing facts: metabolite structure, exposure margins, affected species and organs, and explicit criteria for lifting the hold. Upgrade evidence would be a public FDA clearance to resume enrollment supported by adequate human exposure margins and no emergent clinical pattern.<\/p>\n

Company and Product Background<\/h4>\n

Biohaven is developing BHV-7000, also called opakalim, as a selective Kv7.2\/7.3 activator for focal epilepsy and other neurologic disorders. Kv7 channel opening stabilizes the neuronal membrane and can reduce pathologic firing.<\/p>\n

The development thesis depends on maintaining antiseizure activity with a tolerability profile suitable for chronic use. SK Biopharmaceuticals has agreed to acquire global rights to Biohaven’s Kv7 platform under a transaction announced in August 2026, which remains subject to customary closing conditions including antitrust clearance.<\/p>\n

InSilens Take<\/h4>\n

Importance is high because a pivotal epilepsy program and a recently licensed platform now carry an unresolved regulatory safety question. Direction is negative, not because human harm has been shown, but because enrollment and development optionality are constrained until the metabolite risk is characterized. RISE3’s fully enrolled status preserves a near-term efficacy readout, while RISE2 and follow-on execution bear the clearer delay risk.<\/p>\n

Signal Assessment<\/h4>\n\n\n\n\n\n
Signal Importance<\/strong><\/td>\n5 \/ 5 — a partial clinical hold on a pivotal epilepsy program tied to a pending platform transaction<\/td>\n<\/tr>\n
Signal Direction<\/strong><\/td>\nNegative — enrollment and development optionality are constrained pending metabolite characterization<\/td>\n<\/tr>\n
Confidence in Facts<\/strong><\/td>\nHigh — hold, exposure counts and program status confirmed across regulatory and company disclosures<\/td>\n<\/tr>\n
Confidence in Interpretation<\/strong><\/td>\nModerate — human relevance of the rodent metabolite finding is not yet established<\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

The FDA placed a partial clinical hold on Biohaven’s BHV-7000 epilepsy program after requesting more information about a specific metabolite observed in rodent testing. New enrollment is paused in the ongoing epilepsy studies, while…<\/p>\n","protected":false},"author":1,"featured_media":3050,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,3],"tags":[676,675,678,679,677,680],"class_list":["post-3034","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical","category-therapeutic-indication","tag-bhv-7000","tag-biohaven","tag-epilepsy","tag-kv7-channel","tag-opakalim","tag-sk-biopharmaceuticals"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3034","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3034"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3034\/revisions"}],"predecessor-version":[{"id":3054,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3034\/revisions\/3054"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3050"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3034"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3034"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3034"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}